Skip to content

Evaluation of the effectiveness of MedEx Wellness

Evaluation of the MedEx Wellness programme as a public health model for community-based chronic illness rehabilitation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10351412
Enrollment
104
Registered
2016-01-26
Start date
2015-09-25
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic illness, primarily: 1. Cardiovascular disease 2. Peripheral arterial disease 3. Pulmonary disease (including chronic obstructive pulmonary disease, pulmonary fibrosis) 4. Diabetes 5. Cancer Circulatory System Chronic illness, primarily: 1. Cardiovascular disease 2. Peripheral arterial disease 3. Pulmonary disease (including chronic obstructive

Interventions

All participants will attend DCU for 3 days of testing. On Day 1 participants will have a blood sample taken, height, weight, waist and hip circumference measured, complete a questionnaire and some s

Sponsors

Health Service Executive
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or over 2. Established non-communicable disease

Exclusion criteria

Exclusion criteria: 1. Uncontrolled cardiovascular conditions 2. Significant musculoskeletal or neurological conditions, cognitive decline, mental illness or intellectual disability that restricts participation in a physical training programme

Design outcomes

Primary

MeasureTime frame
Cardiorespiratory fitness measured using the 6 minute walk test at baseline, 3, 6 and 12 months.

Secondary

MeasureTime frame
1. Quality of life measured using Medical Outcomes Study Short Form-12 and disease specific measures (COPD Assessment Tool, Functional Assessment of Cancer Therapy, Walking Impairment Questionnaire) at baseline, 3, 6 and 12 months 2. Daily physical activity measured using accelerometry and the International Physical Activity Questionnaire at baseline, 3, 6 and 12 months 3. Health care utilisation measured using at baseline from patient records and throughout the trial using a healthcare utilisation diary at baseline, 3, 6 and 12 months 4. Blood pressure using a 24 h ambulatory blood pressure monitor at baseline, 3, 6 and 12 months 5. Lipids measured by a blood sample at baseline, 3, 6 and 12 months 6. Body composition measured using body mass index and waist-to-hip ratio at baseline, 3, 6 and 12 months 7. Strength measured using the sit-to-stand test and handgrip test at baseline, 3, 6 and 12 months 8. Flexibility measured using the sit-and-reach test at baseline, 3, 6 and 12 months 9. Cognitive function measured using the cognitive reserve questionnaire, the Attention Network Task and the Luck and Vogel Visual Working Memory Task at baseline, 3, 6 and 12 months 10. Claudication time measured by the Gardner claudication treadmill test at baseline, 3, 6 and 12 months 11. Respiratory function measured by spirometry at baseline, 3, 6 and 12 months 12. Falls risk measured using the Timed Up and Go Test at baseline, 3, 6 and 12 months

Countries

Ireland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 27, 2026